MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer
Patrick Neven(KU Leuven), George W. Sledge(Caris Life Sciences (United States)), Peter A. Kaufman(University of Vermont), Olga Burdaeva(Universitair Ziekenhuis Leuven), Antonio Llombart‐Cussac(MedSIR (Spain)), Joohyuk Sohn(Yonsei University), Stephen Johnston(Royal Marsden NHS Foundation Trust), PierFranco Conte(University of Padua), Xavier Pivot(Levi Strauss (United States)), Nadine Haddad(Eli Lilly (United States)), Norikazu Masuda(Kyoto University), Meena Okera(Universitair Ziekenhuis Leuven), Karla Hurt(Eli Lilly (United States)), Masakazu Toi(Mukogawa Women's University), Kenichi Inoue(Universitair Ziekenhuis Leuven), Yi Lu(Shandong Provincial Hospital), Han Koh(Universitair Ziekenhuis Leuven), Eva‐Maria Grischke(Universitair Ziekenhuis Leuven)
Cited by 16
Related Papers
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k